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Based on existing data and previous work, a series of studies is
proposed as a basis toward a pragmatic early step in transforming toxicity testing. These studies were assembled into a datadriven framework that invokes successive tiers of testing with
margin of exposure (MOE) as the primary metric. The first tier
of the framework integrates data from high-throughput in vitro
assays, in vitro-to-in vivo extrapolation (IVIVE) pharmacokinetic
modeling, and exposure modeling. The in vitro assays are used to
separate chemicals based on their relative selectivity in interacting with biological targets and identify the concentration at which
these interactions occur. The IVIVE modeling converts in vitro
concentrations into external dose for calculation of the point of
departure (POD) and comparisons to human exposure estimates
to yield a MOE. The second tier involves short-term in vivo studies, expanded pharmacokinetic evaluations, and refined human
exposure estimates. The results from the second tier studies
provide more accurate estimates of the POD and the MOE. The
third tier contains the traditional animal studies currently used to
assess chemical safety. In each tier, the POD for selective chemicals is based primarily on endpoints associated with a proposed
mode of action, whereas the POD for nonselective chemicals is
based on potential biological perturbation. Based on the MOE,
a significant percentage of chemicals evaluated in the first 2 tiers
could be eliminated from further testing. The framework provides
a risk-based and animal-sparing approach to evaluate chemical
safety, drawing broadly from previous experience but incorporating technological advances to increase efficiency.

Key Words: in vitro and altenatives; biotransformation and
toxicokinetics; predictive toxicology; risk assessment; safety
evaluation; exposure.

Shortly after the turn of the century, there was increasing recognition and acceptance within government agencies that new
approaches were needed to evaluate the safety of the relatively
large number of chemicals in commerce and the environment
(EPA, 2003; Kavlock et al., 2005; Meek and Armstrong, 2007;
NTP, 2004). Following this recognition, the release of the National
Research Council’s Report “Toxicity Testing in the 21st Century:
A Vision and a Strategy” (NRC, 2007) initiated a broad-based
movement in the toxicology community to reassess how toxicity
testing and risk assessment are performed. Since the release of the
report, multiple efforts in the United States and abroad have added
to the momentum with the shared goal of transitioning toxicity
testing and risk assessment from an outdated, inefficient, costly,
and animal-centric process to one that is more efficient, economical, less animal intensive, and more relevant to human health by
utilizing new technologies that provide a better understanding of
the underlying biological system. However, the majority of these
efforts have focused more on a vision of how things should be
done rather than the development of a pragmatic path forward that
can be iteratively refined as greater understanding is achieved.
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Over the past 5 years, a series of studies has been conducted
that together may contribute first steps toward executing the
shared vision. This article considers the implications of these
studies and develops a new, data-driven tiered toxicity testing
framework with potentially broad, international application
across multiple regulatory agencies. The framework evolved
from tiered approaches developed previously to address regulatory mandates to prioritize and assess large numbers of substances (Meek and Armstrong, 2007; Meek et al., 2011). The
primary application of the proposed framework is for chemicals with little or no safety-related data. In the United States,
the proposed framework could, for example, be applied to new
and legacy manufactured chemicals regulated under the Toxic
Substances Control Act (TSCA). Conceptually, it could also be
applied to other nonpharmaceutical chemicals that have defined
toxicity testing requirements, such as pesticides. In Europe, the
proposed framework could be applied to identify substances
of concern within Registration, Evaluation, Authorization and
Restriction of Chemicals (REACH) that may have adverse

effects that are not indicated in the basic information requirements linked to production volume.

Tier 1

The first tier of the proposed framework consists of 5 components—(1) use of high-throughput in vitro assays to separate
chemicals into selective and nonselective modes of action; (2)
in vitro genotoxicity assays to identify potential genotoxic and
nongenotoxic chemicals; (3) in vitro-to-in vivo extrapolation
(IVIVE) pharmacokinetic modeling to convert in vitro assay
concentrations to applied doses; (4) high-throughput exposure
modeling to estimate human exposures to chemicals; and (5)
calculation of a margin of exposure (MOE) (Fig. 1). The data
collection and analysis associated with each of these components would ideally occur simultaneously for inclusion in
a Tier 1 data package associated with each chemical, analogous to the chemical dossiers currently being assembled for

Fig. 1. A flowchart outlining Tier 1 in the proposed framework. The green boxes illustrate the Tier 1 data package that includes experimental data and computational modeling results that serve as inputs into the framework. The yellow boxes are separate chemical categories determined by the in vitro genotoxicity
assays and the high-throughput in vitro screening assays. For the selective chemicals, the red box represents the determination of the tentative mode of action based
on which high-throughput in vitro assays were selectively activated or inhibited. The blue and orange boxes represent the estimation of the point of departure and
MOE using additional pharmacokinetic and exposure information, respectively. For those chemicals with a MOE greater than a defined cutoff, no further testing is
performed, and Tier 1 reference values are published. Chemicals with a MOE less than the cutoff are advanced to Tier 2. Abbreviation: MOE, margin of exposure.
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REACH. Within the current framework, the high-throughput
in vitro screening would be composed of assays that are similar
to those employed in the ToxCast project (Houck et al., 2009;
Judson et al., 2010; Knudsen et al., 2011; Martin et al., 2010;
Reif et al., 2010; Rotroff et al., 2010a). The in vitro ToxCast
assays are primarily repurposed biochemical and cell-based
assays used in drug discovery and cover 327 genes and 293
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
(Kavlock et al., 2012). The details surrounding their selection
and application have been discussed in the publications cited
earlier. Although this selection of in vitro assays may not be
ideal for covering the mechanistic landscape of chemically
mediated toxicity, the ToxCast data set is the largest currently
available for establishing the associations underlying this
framework and provides a significant (though recognizably
imperfect) starting point for a pragmatic path forward that can
be refined as additional experience is acquired.
In Vitro Assays for Bioactivity
In the ToxCast phase I effort, 309 unique chemicals were
screened in more than 600 in vitro assays. The 309 chemicals were primarily pesticides and high-production volume
chemicals for which significant in vivo animal testing has
been performed (Judson et al., 2009; Martin et al., 2009a).
Although prediction of specific in vivo hazards with the current set of ToxCast in vitro assays is limited (Thomas et al.,
2012a; Wetmore et al., 2012a), the in vitro assays do provide a
broad biological profile of the potential proximal biochemical
and cellular targets for a chemical. Instead of using the highthroughput in vitro assays to predict hazard, the initial role of
high-throughput in vitro toxicity screening in our framework
is to separate chemicals into either those that cause toxicity
A.

primarily through nonselective interactions with cells and cellular macromolecules or those that act through more selective
interactions (eg, receptor-mediated chemicals).
To demonstrate how chemicals could be separated into these
categories, the ToxCast phase I data were analyzed for surrogate measures of selectivity. Additional work in this area will
need to be performed to identify which selective interactions
are important for toxicity. The ToxCast in vitro assays were
first grouped by gene to eliminate redundancy. For example, all
of the in vitro assays evaluating the binding or transcriptional
activation of estrogen receptor alpha (ESR1) were grouped
together. The in vitro assays that did not correspond to a specific gene (eg, general cytotoxicity assays) were removed from
the analysis. If any of the in vitro assays associated with a gene
possessed an AC50 value (concentration at 50% of maximum
activity), then the chemical was considered to have activity (ie,
either activates or inhibits) toward that gene. Thus, the more
genes with AC50 values, the less selective a chemical would
be. For the ToxCast phase I chemicals, approximately 80%
of chemicals have activity toward 10 or more genes, and the
average chemical has activity toward approximately 20 genes
(Fig. 2A).
A complementary measure of selectivity expands on this concept and takes into consideration the dose range across which
the different in vitro assays were activated. For each chemical,
the in vitro assays were again grouped by gene, and the in vitro
assays that did not correspond to a specific gene were removed
from the analysis (eg, general cytotoxicity assays). The potency
of each chemical toward a specific gene was summarized by
taking the minimum AC50 value among the associated in vitro
assays. For example, if there were 5 in vitro assays evaluating
the binding or transcriptional activation of ESR1, the potency
B.
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Fig. 2. Cumulative frequency plots summarizing the selectivity of the ToxCast phase I chemicals across the high-throughput in vitro assays. The in vitro
assays were grouped by gene to eliminate redundancy. A, The number of genes with an AC50 value for each chemical. This represents the number of genes activated
or inhibited by a chemical at any concentration. All 309 ToxCast phase I chemicals were used in this analysis. B, The ratio between the minimum AC50 and the
10th percentile for each chemical. This represents the ratio between the concentration at which the most sensitive gene-based assay is activated, and the concentration at which 10% of the gene-based assays are activated. Only 173 ToxCast phase I chemicals activating or inhibiting > 20 gene-based high-throughput in vitro
assays were used in this analysis.
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value for the most sensitive assay was selected. For each chemical, the summary values for each gene were then sorted, and
the lowest summary value across all genes was divided by the
10th percentile. In other words, for each chemical, the potency
of the in vitro assay for the most sensitive gene was divided
by the relative potency when 10% of the genes were affected.
According to this measure of selectivity, approximately 80% of
the ToxCast phase I chemicals have a ratio of 3 or less between
the most sensitive gene target and the 10th percentile (Fig. 2B).
Taken together, these data suggest that the majority of chemicals represented in the ToxCast phase I library likely act via
nonselective interactions with cellular macromolecules. These
results may not be that surprising given that most chemicals in
the ToxCast phase I library were nonpharmaceuticals and were
developed either for their functional properties in a range of
different products or pesticidal qualities and not optimized to
interact specifically with a target protein.
In Vitro Assays for Genotoxicity
In addition to separating chemicals based on selectivity,
chemicals are also grouped based on their genotoxic potential.
This second screen was included as a practical consideration
because most regulatory organizations either label or deal with
substances that are likely to be carcinogenic through a mutagenic mode of action (MOA) differently than those considered
not to be genotoxic. The in vitro assays for genotoxicity within
the proposed framework include the bacterial reverse mutation test and the mammalian cell micronucleus test. These 2
in vitro genotoxicity assays cover the 3 critical genetic endpoints implicated in carcinogenesis and heritable diseases,
namely gene mutations, and structural and numerical chromosome alterations. An expert panel convened by the European
Food Safety Authority (EFSA) concluded that the inclusion
of additional in vitro mammalian cell tests apart from these 2
assays would “significantly reduce specificity with no substantial gain in sensitivity” (EFSA, 2011). This is consistent with
previous recommendations of multiple regulatory agencies and
the International Conference on Harmonization (ICH) for registration of pharmaceuticals (HC, 2000). Adaptations have been
proposed that reduce the number of false positives in the mammalian cell genotoxicity assays (Fowler et al., 2012). If the 2
in vitro genotoxicity assays are negative, the chemical is placed
in the nongenotoxic category, whereas positive results in both
assays would classify the chemical as potentially genotoxic. If
a chemical is positive in one of the in vitro assays, the chemical
would be classified as potentially genotoxic and additional in
vitro or in vivo assays could be performed to confirm the classification. For example, if a chemical is negative in the bacterial reverse mutation test and positive in the mammalian cell
micronucleus test, an in vivo micronucleus analysis could also
be performed to confirm the clastogenicity as recommended in
the standard ICH guidelines (Müller et al., 1999). Ideally, the
in vivo micronuclei studies would be performed in Tier 2 on the
same animals as the transcriptomic analysis using red blood
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cell micronuclei as the endpoint. If a chemical is positive in the
bacterial reverse mutation test and negative in the mammalian
cell micronucleus test, an in vivo gene mutation study could be
performed using 28-day exposures of transgenic rodents carrying mutation reporter genes (OECD, 2011), but this is not cost
effective for many chemicals at this point in time.
In Vitro Pharmacokinetic Assays and IVIVE Modeling
The internal dose of a chemical is an important determinant
of toxicity. To incorporate pharmacokinetics into the framework, data from in vitro hepatic metabolic clearance and plasma
protein binding assays are included in the Tier 1 data package.
These 2 pharmacokinetic parameters are critical for estimating
steady-state blood concentrations. In previous studies, experimental data from the in vitro pharmacokinetic assays were used
to parameterize an IVIVE model to estimate the daily human
oral dose, called the oral equivalent dose, necessary to produce
steady-state in vivo blood concentrations equivalent to the in
vitro AC50 value for each of the high-throughput in vitro assays
(Rotroff et al., 2010b; Wetmore et al., 2012b). Oral equivalent
dose values calculated using this approach are inherently conservative due to various assumptions in the IVIVE modeling
(Rotroff et al., 2010b; Wetmore et al., 2012b). Monte Carlo
sampling was also incorporated into the IVIVE model to
account for interindividual variability and as a basis to derive
an oral equivalent dose that represents the 95th percentile of
the population. A similar approach takes place in our framework and when appropriate, other biokinetic factors within the
in vitro assays will be taken into account (Blaauboer, 2010).
Human equivalent concentrations could also be calculated to
allow comparisons to air exposure levels.
Selective-Acting Chemicals and MOA
For the selective chemicals, the high-throughput in vitro
assays are used to identify key events in a potential MOA.
As previously defined, the MOA is a biologically plausible series of key events leading to an outcome that could be
adverse (Sonich-Mullin et al., 2001). Key events are empirically observable steps that are critical to the outcome. Although
originally and often simply conceptualized as a linear series of
key events, a MOA actually involves interdependent networks
of events with feedback loops. A weight of evidence for the
hypothesized MOA is established based on modified Bradford
Hill considerations including dose response and temporal concordance of key events, consistency and specificity, and biological plausibility (Boobis et al., 2006, 2008).
For application to selective chemicals in Tier 1 of the proposed framework, the key event must be triggered at doses
lower than or equal to doses at which the adverse outcome is
observed (ie, dose concordance between a key event and the
adverse outcome). An example of this approach has been provided for the relationship between in vitro peroxisome proliferator–activated receptor alpha (PPARA) activation and rat liver
proliferative lesions and liver tumors (Wetmore et al., 2012a).
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Among a subset of ToxCast phase I chemicals, 8 were active
in the in vitro PPARA assays and cause proliferative lesions in
the livers of rats, while 4 also cause rat liver tumors. For each
chemical, the in vivo-derived lowest effect level (LEL) and no
effect level for rat liver proliferative lesions and tumors were
overlaid with the oral equivalent dose values for the 3 highthroughput in vitro assays measuring PPARA-related activation
(Fig. 3). In all cases, activation of the PPARA in vitro assays
occurred at or below the dose for the in vivo effects, thereby
demonstrating dose concordance between this potential key
event and the adverse outcome. A similar approach is taken in
the proposed framework. From these selectively activated or
inhibited assays, probable key event(s) will be determined and
the oral equivalent dose value from a relevant in vitro assay will
be compared with doses causing the associated in vivo adverse
outcome (when available).
Apart from dose concordance, the biological relevance linking the in vitro assay to the in vivo adverse outcome will also
be qualitatively assessed. If the in vitro assay representing the
key event demonstrates dose concordance and biological relevance, the oral equivalent dose value will be used as the point
of departure (POD) in a dose-response assessment. It is anticipated that there will be a limited number of MOAs that will
be identified in Tier 1 for the selective chemicals. The MOAs
will have a defined set of criteria based on chemicals that are
known to act through those key events. Additional MOAs will
be added as our biological knowledge improves and the assay
suite is refined.

Nonselective Chemicals and Biological Perturbation
Identifying the MOA will generally be neither efficient nor
economical for the nonselective chemicals because the chemicals will interact with and perturb multiple cellular processes.
In a previous study, rat-specific oral equivalent doses were calculated for 59 ToxCast phase I chemicals and compared with
LEL values for a variety of in vivo apical responses (Wetmore
et al., 2012a). Although not significantly correlated (r2 = .046),
the oral equivalent dose for the most sensitive in vitro assay was
less than the LEL for the most sensitive rat in vivo endpoint for
approximately 95% of the chemicals (Fig. 4A). The LEL values
spanned 38 unique in vivo endpoints across multiple tissue and
organ systems and across reproductive, chronic, and developmental study types. The median difference between the most
sensitive in vitro assay and the most sensitive LEL value was
66-fold (Fig. 4B). These results indicate that the most sensitive in vitro assay was protective regardless of the nature of the
adverse outcome and that bioactivity based on the oral equivalent dose for the most sensitive in vitro assay could be used as a
reasonable estimate of the POD for the nonselective chemicals
in a dose-response assessment.
Human Exposure Characterization
The final component of the Tier 1 data package relates to
exposure. An understanding of human exposure is critical for
placing the dose-response data for toxicity into context and
ultimately assessing health risks. Human exposure estimates

Fig. 3. Comparison of in vivo low effect and no effect doses for rat liver proliferative lesions and the in vitro PPARA-activating oral equivalent doses in the
ToxCast phase I assays. The in vivo effects of 8 chemicals were plotted as LEL (blue triangles) and NEL (yellow triangles). If liver tumors were observed, a red
triangle was placed at the tumorigenic LEL. The in vitro oral equivalent doses were overlaid for the PPARA transactivation assay in HepG2 cells (white circles)
(Martin et al., 2010) and PPARA-regulated HMGCS2 gene expression changes in primary human hepatocytes at 24 h (white squares) and 48 h (white diamonds)
(Rotroff et al., 2010a). The oral equivalent doses for each assay were calculated at the 1 and 10µM concentrations where intrinsic clearance was measured and
connected with a solid line. The gray bars span 10-fold below the NEL and 10-fold above the highest of the LEL to illustrate potential uncertainties in the approximations associated with the oral equivalent doses. The graph and associated data are from Wetmore et al. (2012a). Abbreviations: LEL, low effect levels; NEL, no
effect levels; PPARA, peroxisome proliferator–activated receptor alpha.
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Fig. 4. A comparison of ToxCast in vitro assay possessing the lowest oral equivalent dose with the in vivo response possessing the lowest LEL for each
chemical. A, Scatter plot of the log-transformed minimum LEL in ToxRefDB (y-axis) versus the minimum oral equivalent dose among the approximately 600
high-throughput in vitro ToxCast assays (x-axis) for each chemical. A subset of 59 ToxCast phase I chemicals were evaluated. B, Histogram and summary statistics of the log10-transformed ratios of the minimum LEL from the guideline animal studies in ToxRefDB divided by the minimum oral equivalent dose among the
approximately 600 high-throughput in vitro assays. Nontransformed values for each of the summary statistics are provided in parentheses. The graph and associated data are from Wetmore et al. (2012a). Abbreviation: LEL, low effect level.

can be obtained from multiple sources and are associated with
varying levels of uncertainty, depending principally on the
complexity and accuracy of input data and model assumptions. Simple surrogates such as use and emission profiling and
physicochemical properties offer potential to reasonably discriminate amongst chemicals with respect to exposure potential
(Arnot et al., 2012; Meek and Armstrong, 2007; Meek et al.,
2011).
For some of the Tier 1 chemicals, human exposure estimates can be derived from biomonitoring data such as the U.S.
National Health and Nutrition Examination Survey (NHANES)
(CDC, 2009). Measurements of parent chemical concentrations
in the blood or urinary metabolite concentrations can be used to
infer exposure concentrations using reverse dosimetry methods
(Tan et al., 2007). Using Monte Carlo sampling, probabilistic
information about pharmacokinetics and exposure patterns can
be included to estimate variability in the exposure distribution
across a diverse population (Tan et al., 2007). In Tier 1 of our
framework, a conservative 95th percentile upper confidence
bound on the exposure estimate is used, where available.
For chemicals without biomonitoring data, it is proposed to
use a high-throughput exposure modeling that has been developed by combining existing environmental fate and transport
models (ie, far field) with an empirical adjustment for indoor or
consumer exposure (ie, near field) (Wambaugh et al., 2013). In
addition to a high-level assessment of consumer use, physicochemical properties and an estimate of environmental release
are required as inputs to the model. The approach was calibrated

using 82 chemicals from NHANES and then used to predict
human exposures for 1,936 chemicals. The approach provides
uncertainty bounds on the aggregate exposure estimates. The
95th percentile upper confidence bound of the exposure estimate is utilized in our framework.
MOEs
The human exposure estimates are combined with the POD
from the dose-response assessment to calculate a MOE. For
the components of the framework discussed above, the MOE
is based on administered dose. A second alternative is the calculation of MOE based on internal dose using human biomonitoring data. For this alternative, concentrations in blood are
directly compared with the concentrations in the in vitro assays
so as to provide a direct measure of a MOE (Aylward and
Hays, 2011; Aylward et al., 2013). Although not all chemicals
are amenable to biomonitoring measurements, the advantage
of this approach is that it eliminates inherent uncertainty in the
pharmacokinetic and exposure modeling. Interindividual variability could be incorporated by using either the percentiles of
the measured distribution in large biomonitoring studies (CDC,
2009) or estimated from smaller studies using pooled samples
(Caudill, 2010, 2012).
Regardless of whether the MOE is calculated using administered or internal dose, the MOE is the primary metric for
determining whether a substance advances on for consideration
in subsequent tiers. For the selective chemicals, the MOE is
calculated relative to the oral equivalent dose from the in vitro
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assay(s) associated with the proposed key event. For the nonselective chemicals, the MOE will be calculated relative to the
oral equivalent dose for the most sensitive in vitro assay. For
those chemicals with a MOE greater than some defined cutoff, no further testing would be required, whereas chemicals
with a MOE below the cutoff would progress on to Tier 2. In
a previous study on the ToxCast phase I chemicals (Wetmore
et al., 2012a), a Tier 1 MOE cutoff of > 100 would eliminate
additional testing on approximately 40% of chemicals, whereas
a MOE cutoff of > 1000 would eliminate additional testing on
approximately 25% of chemicals (Fig. 5). Although the MOE
cutoff will be primarily set through policy decisions and not
necessarily based solely on scientific criteria, it should be set
to provide adequate protection for susceptible subpopulations.
Reference Values
For those chemicals that do not advance to the next tier, Tier
1 reference values could be used to provide exposure guidelines. For certain regulatory agencies these could be considered
screening-level values, whereas other agencies may wish to
apply them in alternative ways. For the nongenotoxic chemicals, the POD and associated lower confidence bound can be
divided by a set of uncertainty/safety factors to derive a Tier 1
reference value as a basis to provide health-related guidance.
A previous study using in vitro data has provided one possible
approach (Judson et al., 2011). For the genotoxic chemicals,
the POD and associated lower confidence bound can be divided
by uncertainty/safety factors, or, alternatively, a linear, no
threshold dose-response extrapolation could be applied. In this

case, the POD could be assumed to be equivalent to a defined
increase in adverse response (eg, 10%) and used to calculate a
Tier 1 slope factor. However, it should be noted that activation
of the in vitro assays analyzed here cannot yet be quantitatively
linked to a specific incidence in the in vivo adverse response.
Chemicals Not Amenable to In Vitro Screening
Although efforts are underway to broaden the applicability of
high-throughput in vitro screening platforms, certain chemicals,
such as volatile substances, those not soluble in dimethyl sulfoxide or those that bind avidly to plastic, are currently not readily
amenable for high-throughput in vitro screening. In the proposed
framework, these chemicals would be identified using an initial
structure-activity relationship or molecular properties filter and
are automatically directed to Tier 2 for evaluation. No measure
of selectivity would be available for these chemicals, and they
would be assumed to act through nonselective mechanisms.

Tier 2

The second tier of the proposed framework consists of 5
components—(1) short-term in vivo transcriptomic studies
to identify the transcriptional POD values for nonselective
chemicals; (2) in vivo MOA studies to identify POD values for
selective chemicals; (3) in vitro and in vivo pharmacokinetic
studies to improve linkage between internal and applied dose;
(4) refined human exposure estimates; and (5) calculation of a
MOE (Fig. 6). Similar to the first tier, the data collection and

Fig. 5. Cumulative frequency plot of the ratio between in vitro bioactivity relative to human exposure in the most highly exposed subpopulation for the
ToxCast phase I chemicals. The MOE was calculated by comparing the minimum oral equivalent dose across the approximately 600 high-throughput in vitro
ToxCast assays using human pharmacokinetic measurements and in vitro-to-in vivo extrapolation modeling with the exposure estimates for the most highly
exposed subpopulation. The graph and associated data are reproduced from Wetmore et al. (2012a). Abbreviation: MOE, margin of exposure.
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analysis associated with each of these components would ideally occur simultaneously for inclusion in a cohesive Tier 2
data package. The data requirements would be different for the
selective and nonselective chemicals.
Selective-Acting Chemicals and MOA
Focused in vivo MOA studies would be performed on the
selective chemicals to evaluate the putative MOA defined in
Tier 1 and would be defined by the type of MOA proposed.
For proposed nuclear receptor agonists such as the constitutive androstane receptor, pregnane X receptor, or PPARA, these
studies could include knockout and humanized rodent models.
For proposed estrogen receptor agonists, these studies may also
include standard in vivo studies such as the immature rat uterotrophic assay (OECD 440). Following the in vivo MOA studies and consideration of the weight of evidence, qualitative and
quantitative human concordance would be evaluated (Boobis
et al., 2008). The POD for relevant MOAs would be determined
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based on the associated endpoints in the in vivo studies, but
scaled, taking into account relevant kinetic and dynamic data.
Nonselective Chemicals and Biological Perturbation
The premise for analysis of nonselective chemicals has been
developed based on the results of a series of previous studies
examining the relationship between transcriptional and apical
responses (Thomas et al., 2007, 2011, 2012b, 2013). Both noncancer and cancer apical responses were analyzed using benchmark dose (BMD) methods to identify PODs. The dose response
for changes in gene expression was also analyzed using BMD
methods, and the responses were grouped based on signaling
pathways. In a comparison of transcriptional BMD values for
the most sensitive pathway with BMD values for the noncancer
and cancer apical endpoints, there was a high degree of correlation (Thomas et al., 2012b) (Fig. 7). The correlation was
also robust across multiple time points (Thomas et al., 2013).
In this proposed framework, dose-response studies would be

Fig. 6. A flowchart outlining Tier 2 in the proposed framework. The green boxes illustrate the Tier 2 data package that includes experimental data and computational modeling results that serve as inputs into the framework. The chemical categories determined by the in vitro genotoxicity assays and the high-throughput
in vitro screening assays are retained from Tier 1. For the selective chemicals, the light blue box represents the determination of the human relevance of the mode
of action. The blue and orange boxes represent the estimation of the point of departure and MOE using expanded pharmacokinetic and exposure information,
respectively. For those chemicals with a MOE greater than a defined cutoff, no further testing is performed, and Tier 2 reference values are published. Chemicals
with a MOE less than the cutoff are advanced to Tier 3. Abbreviation: MOE, margin of exposure.
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Fig. 7. Scatter plots of the relationship between the BMD values for (A) cancer-related apical endpoints or (B) noncancer apical endpoints and transcriptional
BMD values for the most sensitive signaling pathway following 13 weeks of exposure. The data points were colored based on the target tissue, and symbol shape
represents species. The black line dissecting the graph indicates equivalent apical and transcriptional BMD values. The red lines represent 10-fold difference
between the BMD values. Correlation coefficients (r) and associated p value are included in the lower right hand corner of each panel. The median log2 ratio of
the apical-to-transcriptional BMD values is provided in the upper left hand corner. The antilog of the transformed ratio is provided in parentheses. The graph and
associated data are from Thomas et al. (2013). Abbreviation: BMD, benchmark dose.

performed on the chemical at any single time point between
5 days and 13 weeks in mice and rats of both sexes. A battery of
8 tissues that include those most frequently impacted in rodent
cancer bioassays (liver, lung, mammary gland, stomach, vascular system, kidney, hematopoietic system, and urinary bladder)
would be harvested. These 8 tissues cover 92% and 82% of targets for all mouse and rat carcinogens, respectively (Gold et al.,
2001). For noncancer effects, a previous analysis of 69 different pesticides demonstrated that adverse responses in a chronic
rat bioassay generally occurred at lower doses than either a rat
2-generation reproductive study or a rat developmental toxicity
study (Dourson et al., 1992). In addition, potential reproductive and developmental toxicants could be identified based on
consideration of weight of evidence of available data including structure activity modeling (Blackburn et al., 2011). For
chemicals flagged for these potential responses, additional
tissues and alternate study designs (eg, OECD 421) would be
incorporated to cover potential reproductive and developmental
effects. Gene expression microarray analysis on these tissues
would allow the estimation of pathway transcriptional BMD
and BMDL values. The signaling pathway with the lowest transcriptional BMD value among the analyzed tissues would be
used to derive the POD.
In Vivo and In Vitro Pharmacokinetic Studies and Modeling
The pharmacokinetic data from Tier 1 would also be
expanded through focused in vitro studies and the collection of
additional samples within the existing in vivo studies. Potential

metabolites of each chemical would be identified using rodent
and human microsomes, S9, and plasma. Recent advances in
semiautomated metabolite identification have been made by
combining in silico metabolite prediction software with ultrahigh pressure liquid chromatography and mass spectral analysis (Bonn et al., 2010). In essence, computational approaches
are used to align the raw mass spectral data with a predicted site
of metabolism in order to assign the structure of a metabolite.
In our framework, these studies are performed to qualitatively
identify probable metabolites in both the rodent and human.
Reactive metabolites will also be evaluated using primary
hepatocytes for analysis of lipid peroxidation, reactive oxygen
species generation, and glutathione depletion.
Apart from the metabolite characterization, blood samples
will be collected in either the in vivo mode-of-action studies
for the selective chemicals or the in vivo transcriptomic studies
for the nonselective chemicals. A previous study has demonstrated that the collection of blood samples at 3 specific time
points during a single day of a repeat dose study was sufficient
to estimate systemic bioavailability of a chemical (Saghir et al.,
2006). The human volume of distribution of each chemical
will be estimated using quantitative structure-activity relationships (Peyret and Krishnan, 2011; Peyret et al., 2010; Poulin
and Theil, 2002; Rodgers and Rowland, 2006, 2007; Rodgers
et al., 2005), and the oral bioavailability will be estimated using
the in vitro bidirectional permeability assay with Caco-2 cells
(Wetmore et al., 2012b). Together with the metabolic clearance
and plasma protein binding data from the Tier 1 studies, the
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combined data will be used to develop pharmacokinetic models
to define the administered dose in humans leading to the active
internal doses seen in the Tier 2 studies.
Human Exposure Characterization
Human exposure estimates from Tier 1 could potentially be
refined through a combination of experimental measurements
of physical-chemical properties and environmental degradation
rates, refined release rates, detailed consumer and indoor use
profiling, product formulation data, environmental and household exposure factor estimates, and targeted biomonitoring studies. The fate and transport models used for the high-throughput
exposure modeling in Tier 1 rely heavily on physical-chemical
properties, environmental half-lives, and release rates. For
many chemicals, the physical-chemical properties and environmental half-lives are not experimentally available and have to
be estimated using quantitative structure-activity relationships
(Wambaugh et al., 2013). Higher throughput methods are available for measuring both physical-chemical properties (Kerns,
2001) and the degradation half-lives in some environmental
media (Hussain et al., 2007). In our proposed framework, these
higher throughput methods could be applied to all Tier 2 chemicals. In addition, more accurate industrial release rates could be
obtained from industry. The combination of these data may be
used to reduce the uncertainty in the fate and transport models.
To refine the near-field component of the exposure estimates,
one option is to obtain more detailed consumer and indoor use
profiles and product formulation data. These use profiles and
formulation data could be aggregated from existing online
databases such as the National Library of Medicine (NLM)
Hazardous Substances Data Bank, NLM Household Products
Database, Walmart’s online material safety data sheets search
engine, U.S. Environmental Protection Agency’s (EPA)
Exposure Factor Handbook (EPA, 2011), and the Substances
in Products in the Nordic Countries (SPIN) database. A significant amount of the exposure-related data aggregation is
currently underway (Egeghy et al., 2012; Mattingly et al.,
2012). In the proposed framework, the more detailed use profile and product formulation data could potentially be used to
select relevant consumer exposure models that exist for specific
exposure scenarios (Kephalopoulos et al., 2007). The resulting
near-field exposure estimates could be combined with the farfield exposures to obtain an aggregated exposure estimate.
MOEs
Similar to Tier 1, the human exposure estimates will be
combined with the POD from the in vivo dose-response studies
to calculate a MOE based on administered dose. Within Tier
2, additional alternatives could be explored to integrate highthroughput biomonitoring studies in order to calculate a MOE
based on internal dose. Advances in analytical chemistry and
Fourier transform mass spectrometry have enabled what has
been termed “high-performance metabolic profiling” (Johnson
et al., 2010; Park et al., 2012; Soltow et al., 2011). Using these
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methods, up to 7,000 chemicals can be measured in 20 µl of
biofluids in 20 min (Soltow et al., 2011). The high-performance metabolic profiling could be applied to biomonitoring
samples from a range of different subpopulations, and mass
labeled standards could be used to quantify specific chemicals
of interest. The concentrations in the human blood samples
would then be compared with estimated blood concentrations
at the POD in the in vivo transcriptomic or MOA studies to
provide a MOE.
Regardless of whether the MOE is calculated using administered or internal dose, the POD for the selective chemicals
will be based on the associated endpoints in the in vivo MOA
studies, whereas the POD for the nonselective chemicals will
be derived from the signaling pathway with the lowest transcriptional BMD value across all analyzed tissues. For those
chemicals with a MOE greater than a defined cutoff, no further testing would be required, whereas chemicals with a MOE
below the cutoff would progress on to Tier 3. Using data from
ToxRefDB on the in vivo LEL values for the ToxCast phase
I chemicals (Knudsen et al., 2009; Martin et al., 2009a,b) and
the corresponding human exposure estimates (Rotroff et al.,
2010b; Wetmore et al., 2012b), MOE values were calculated
using the minimum in vivo LEL value (ie, the most sensitive in
vivo endpoint) and the exposure estimate for the most highly
exposed subpopulation. Assuming that this ratio is representative of the MOE values that will be obtained from Tier 2 in our
proposed framework, a MOE cutoff of > 100 would eliminate
additional testing on approximately 97% of chemicals, whereas
a MOE cutoff of > 1000 would eliminate testing on approximately 85% of chemicals (Fig. 8).
Reference Values
For those chemicals that are set aside from additional testing, Tier 2 reference values could be published to provide
exposure guidelines. Similar to those described for Tier 1,
the Tier 2 reference values may have different applications
among regulatory agencies. For the nongenotoxic chemicals, the POD and associated lower confidence bound can be
divided by a set of uncertainty/safety factors to derive a Tier
2 reference value as a basis to provide health-related guidance. For the genotoxic chemicals, the POD and associated
lower confidence bound can be divided by uncertainty/safety
factors, or, alternatively, a linear, no threshold dose-response
extrapolation could be applied. The POD for the most sensitive pathway among the analyzed tissues could be used as
the equivalent to the BMDL10 for a tumor response (ie, the
lower confidence limit of the BMD associated with a 10%
increased risk of tumors). The rationale for this equivalence is
that our data showed that transcriptional BMD values for the
most sensitive pathway were, on average, within a factor of 2
of the BMD10 values for tumor responses in the corresponding rodent bioassays (Thomas et al., 2013). The pathway
transcriptional BMDL value could then be used to estimate a
slope factor and the desired risk specific dose.
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Fig. 8. Cumulative frequency plot of the ratio between the in vivo LEL relative to human exposure in the most highly exposed subpopulation for ToxCast
phase I chemicals. The MOE was calculated by comparing the minimum LEL value of the guideline animal studies in ToxRefDB (Knudsen et al., 2009; Martin
et al., 2009a,b) divided by the exposure estimates for the most highly exposed subpopulation (Wetmore et al., 2012b). Abbreviations: LEL, low effect level; MOE,
margin of exposure.

Tier 3

The toxicity testing proposed for chemicals passing into Tier
3 is not explicitly defined but would be conceptually equivalent to the traditional in vivo studies performed on high-value
chemicals with significant potential for human exposure.
Alternatively, they would be specified based on understanding
of the toxicological profile acquired in lower tier testing. These
studies could include rodent cancer bioassays, developmental
toxicity studies, and reproductive toxicity studies. Depending
on the MOE cutoff values imposed, it is anticipated that the
majority of chemicals will be screened out in the preceding tiers
and the estimated number of chemicals requiring these studies
would be between 3% and 15%. Testing for these remaining
compounds could be prioritized by endpoint and compounds
based on the results from both Tier 1 and 2 studies.
Summary

The proposed framework integrates data from new technologies into toxicity testing using what is currently the best available science. The proposed framework provides a risk-based,
efficient, and animal-sparing approach to evaluate chemical
safety. It is consistent with and draws broadly from previous
experience in risk assessment but incorporates recent advances
in technology to increase efficiency. The framework relies on
the initial separation of chemicals into selective and nonselective MOAs. The prevailing thought is that the MOA approach

can be efficiently applied to all chemicals. In our view, applying the MOA approach to the nonselective chemicals is neither
practical, scientifically justifiable, nor consistent with evolving
experience in increasing efficiency in risk assessment. First,
imposing an MOA approach on these chemicals would waste
valuable resources and unnecessarily delay decision making
because each MOA requires agreement on the underlying key
events followed by extensive peer review. Second, for chemicals which interact with numerous molecular targets in a cell,
identifying a prevailing MOA among many operating in parallel will be a complex and potentially uncertain process. Thus,
these efforts should be focused on the selective chemicals
where a series of standardized MOAs could be developed that
are associated with specific cellular targets.
A shift in thinking will also be required for the nonselective chemicals. The current hazard-based labeling approach
that relies on apical responses will need to be transitioned to a
“region of safety” approach where the most sensitive adverse
apical effect is not known, but disruption of important biologic
processes can be measured and the dose response characterized. The subsequent decisions are based on potential biological perturbations (Andersen and Krewski, 2010). This shift in
thinking may be more challenging to implement due to the
entrenched reliance on apical responses, the potentially conservative nature of utilizing molecular perturbations as PODs,
and the difficulty in associating molecular perturbations with
actual risk. To increase experience in using these approaches,
the proposed framework could be tested in human health
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risk assessment programs tasked with evaluating chemicals
with limited toxicity data, such as the U.S. Environmental
Protection Agency’s (EPA) Superfund Health Risk Technical
Support Center (STSC; http://www.epa.gov/superfund/health/
research.htm). This program evaluates chemicals of interest to
Superfund that commonly possess limited toxicity data compared with the generally more data-rich chemicals assessed by
the EPA’s Integrated Risk Information System (IRIS). Once a
critical mass of chemicals has been evaluated, a reassessment
of the framework would identify the strengths and limitations
as well as incorporate any subsequent advances in technology
or biological knowledge.
Several organizations have proposed using high-throughput
in vitro assays for prioritizing chemicals for in vivo testing. In
theory, under prioritization, all chemicals would still need to
be tested, just in a different order. However, due to resource
constraints, chemicals of lower concern may never be tested in
practice. In the proposed framework, only a subset of chemicals
would likely be elevated for additional testing in successive tiers
based on the MOE, resulting in a significant monetary, time, and
animal savings. However, it should be noted that depending on
the needs of a given regulatory program, the appropriate “capture rate” for testing at each tier could be established, based on
transparent delineation of considerations addressing this aspect
as one of the components for acceptability of MOEs.
The proposed framework and underlying data sources also
have some potential limitations that require improvement during the implementation of the framework. First, the current battery of in vitro assays may not represent one or more critical
MOAs, which may falsely identify a chemical as nonselective.
In this scenario, the POD for the chemical would be the most
sensitive in vitro assay while the chemical may actually selectively activate or inhibit a pathway, process, or macromolecule
at a significantly lower dose. In the proposed framework, it is
important that the initial screen for selectivity be as comprehensive as possible. To broaden the biological space covered
in Tier 1, additional in vitro assays could be included from
those reported in PubChem (Li et al., 2010). Alternatively, in
vitro transcriptomic measurements could also be performed in
concentration-response format across a panel of cell lines that
express a diverse range of cellular targets and pathways (Lamb,
2007).
The second limitation that requires improvement is the properties associated with the current ToxCast in vitro assays. The
limitations of these properties have been previously discussed
(Judson et al., 2011; Thomas et al., 2012a) but include the
lack of metabolism, use of single cell types that fail to replicate tissue-level cell-cell interactions, lack of biological context, and the short-term nature of the in vitro assays relative to
responses following chronic duration exposure. As these assays
are improved, the new assays can be incorporated into the Tier
1 screening process.
A third limitation is related to the exposure modeling
across the tiers. In the current state of exposure modeling, the
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environmental fate and transport models (ie, far field) are generally more mature and have been more thoroughly validated
than the indoor and consumer exposure models (ie, near field).
Ironically, far-field exposures are usually the least important by
orders of magnitude when considering the aggregate exposure
to a particular chemical. The lack of well-validated indoor and
consumer exposure models can be at least partially attributed
to both a lack of data on the use and the relative quantity of
specific chemicals in various consumer products and the lack of
measurement data for model validation (Egeghy et al., 2012).
If exposure information is going to be used to make better
decisions on chemical safety in either this framework or more
generally, then the science relating to predicting indoor and
consumer exposure needs to be improved.
A fourth limitation is adapting these new approaches to risk
assessment of chemical mixtures. Current mixtures risk assessment methods focus either on component-based approaches
or whole mixture toxicity evaluations (EPA, 2000). The
framework described in this manuscript is readily adapted to
a components-based approach. For example, for the selective
chemicals that target the same protein or pathway, in vivo relative potency factors could be estimated using the results from
the associated in vitro assays and IVIVE pharmacokinetic modeling to convert in vitro assay concentrations to applied doses.
Mixtures risk estimates could then be derived using a relative
potency factor approach similar to the toxic equivalency factors used for dioxins and dioxin-like chemicals (Van den Berg
et al., 2006). Alternatively, a hazard index approach could be
applied to all chemicals of concern (EPA, 2000). A hazard quotient could be estimated by dividing the estimate of the human
exposure by the Tier 1 reference value for each chemical. The
cumulative hazard index is then estimated by summing the
hazard quotients for all chemicals of concern. If the hazard
index is > 1, this would indicate possible exposures of concern.
Finally, the new in vitro approaches are also well suited for
whole mixtures toxicity evaluation. The advantage of in vitro
methods is that large numbers of relevant mixtures could be
evaluated for biological activity. The proposed in vitro cumulative risk approach has many of the same limitations as the
in vitro risk approach for individual chemicals. Although this
proposed in vitro cumulative risk approach is theoretically possible, additional experimental data needs to be collected using
this approach prior to application.
In other initiatives, frameworks have or are being developed
that should be considered as complementary or congruent to
that proposed here. For example, the Health and Environmental
Sciences Institute (HESI) RISK21 project has proposed a more
general and overarching scheme that easily incorporates the
tiered evaluation approaches in this proposed framework. The
WHO framework on MOA is currently being updated to reflect
increasing experience in hypothesizing potential effects based
on information pertaining to putative key events in established
modes of action from appropriate in vitro or in silico systems
and other evidence.
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In summary, the proposed framework provides a risk-based,
rapid, cost-effective, and animal-sparing means to evaluate
chemicals for safety. The framework represents only an initial step that can be iteratively refined along the way to a fully
knowledge-based approach for evaluating chemical safety.
Progress toward a better future in chemical safety assessment
will require implementation of pragmatic approaches, such as
the proposed framework or one similar to it, by national regulatory agencies, cooperation of international organizations such as
the Organization for Economic Co-operation and Development
(OECD), and stakeholder education and involvement.
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